SUPPLYING THE FIGHT AGAINST CANCER
In the fight against cancer, hope, health and progress are being held back by supply chains. Nusano is working to remove these barriers and usher in a new era in cancer care.
REVOLUTIONIZING RADIOISOTOPE PRODUCTION
The promise of medical radioisotopes has for too long been held back by technical limitations, supply outages, and waste stream concerns. The Nusano production platform is poised to address all these issues – stabilizing supply chains, and making a wide variety of isotopes available to drugmakers, researchers, and clinicians.
At the core of many oncology therapies are radioisotopes. However, increasingly limited supply inhibits patient outcomes and the development of new therapies.
Innovation
Advancements with radioisotopes
Nusano is combining time-proven technology from universities and world-class research centers with our own breakthrough, patented particle acceleration technology. The result is the first significant advancement in medical radioisotope production in decades – a platform fitting the needs of today and designed for cancer-fighting radiopharmaceuticals of tomorrow.
Inspiration
Life Saving Benefits
Health care has used radioisotopes for decades. But, if supply does not keep up with demand, patients will lose out on the benefits of these lifesaving, proven tools.
Implications
a healthy tomorrow
Nusano’s patented technologies and methods are poised to transform radioisotope production and usher in an exciting new era in cancer care. When it opens, our state-of-the-art facility in West Valley City, Utah will produce radioisotopes quickly, efficiently, and affordably. This will make desperately needed resources available to hospitals and cancer clinics around the world and offer those with life-threatening diseases hope for a healthier tomorrow.
NUSANO HOLDS FULL RIGHTS TO ITS UNIQUE TECHNOLOGY
Detailed technical information and validation data is available to qualified investors and research partners. If interested in learning more about the Nusano production platform, please contact us.
Nusano Medical Radioisotopes
Nusano is a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, and to serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services. Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries.
Working to Improve Patient Care
Supply chains should not determine a patient’s treatment options. Yet, all too often, this is what happens.
Next-generation cancer therapies are being held back because critical components (medical radioisotopes) needed for advanced therapies and new methods of diagnosis are scarce. Many existing manufacturing techniques for the production of radioisotopes and the facilities relied upon by drugmakers around the world are aging, outdated, inefficient and have limited production capabilities. This threatens the ability to meet current patient needs for medical radioisotopes and stifles innovation.
We need new solutions. That’s where Nusano comes in.
Nusano is a medical radioisotope supplier with a first-of-its-kind radioisotope production platform. Medical radioisotopes are tiny tracers used by doctors to diagnose and treat cancer, Alzheimer’s, heart disease and other diseases. Doctors use medical radioisotopes like flashlights to light up areas inside the body. They can see how blood is flowing, how organs are functioning, even how cells are growing. Advanced medicines and treatment methods also use medical radioisotopes to target and eliminate cancer cells with precision.
Health care has used radioisotopes for decades. But supply hasn’t kept up with demand, leaving patients without the benefits of these lifesaving, proven tools.
Nusano’s patented technologies and methods are poised to transform the production of radioisotopes and help usher in an exciting new era in health care. Opening in 2025, our state-of-the-art radioisotope production platform in West Valley City, Utah will produce radioisotopes quickly, efficiently and affordably. This will make desperately needed medical radioisotopes available to patients around the world and offer those with life-threatening diseases hope for a healthier tomorrow.
Why does Nusano exist?
- We believe no patient should be denied the cancer care they need simply because some options are in short supply or unavailable.
- Nusano is a radioisotope production company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market.
How does Nusano contribute to the radiopharmaceuticals development?
- Nusano is medical radioisotope supplier to drugmakers, hospitals and clinics. With a reliable supply of radioisotopes, these teams can then formulate treatments and next-generation pharmaceuticals needed to advance the fight against cancer.
- Nusano has developed a radioisotope production platform that is smaller, safer and more efficient than existing technologies to reliably produce medical radioisotopes at the heart of next-generation cancer treatments and diagnosis techniques.
- Radioisotopes are essential components in the active pharmaceutical ingredients (API) of a category of new and emerging cancer therapies, known as radiotherapeutics. Existing supply chains for these treatment-enabling resources are often strained, posing a risk to patient care, clinical trials, and ongoing drug development.
What does Nusano offer?
- Nusano is a radioisotope production company making medical radioisotopes that can be targeted to cancer cells with precision –enabling new ways to detect and eradicate cancer and other deadly diseases.
- Nusano’s proprietary radioisotope production platform can produce more than 25 isotopes of interest to medicine.
- Nusano expects to begin supplying non-carrier-added lutetium-177 (n.c.a. Lu-177) in 2025 and actinium-225 (Ac-225) in 2026.